9 01/04/2024 31/03/2025 2025-03-31 false false false false false false false true false false true false false false true false true false No description of principal activities is disclosed 2024-04-01 Sage Accounts Production 25.0 - FRS102_2025 xbrli:pure xbrli:shares iso4217:GBP 04654503 2024-04-01 2025-03-31 04654503 2025-03-31 04654503 2024-03-31 04654503 2023-04-01 2024-03-31 04654503 2024-03-31 04654503 2023-03-31 04654503 core:PlantMachinery 2024-04-01 2025-03-31 04654503 core:MotorVehicles 2024-04-01 2025-03-31 04654503 core:NetGoodwill 2024-04-01 2025-03-31 04654503 bus:RegisteredOffice 2024-04-01 2025-03-31 04654503 bus:LeadAgentIfApplicable 2024-04-01 2025-03-31 04654503 bus:Director1 2024-04-01 2025-03-31 04654503 core:NetGoodwill 2025-03-31 04654503 core:FurnitureFittingsToolsEquipment 2024-03-31 04654503 core:MotorVehicles 2024-03-31 04654503 core:FurnitureFittingsToolsEquipment 2025-03-31 04654503 core:MotorVehicles 2025-03-31 04654503 core:WithinOneYear 2025-03-31 04654503 core:WithinOneYear 2024-03-31 04654503 core:AfterOneYear 2025-03-31 04654503 core:AfterOneYear 2024-03-31 04654503 core:ShareCapital 2025-03-31 04654503 core:ShareCapital 2024-03-31 04654503 core:RetainedEarningsAccumulatedLosses 2025-03-31 04654503 core:RetainedEarningsAccumulatedLosses 2024-03-31 04654503 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 04654503 core:NetGoodwill 2024-03-31 04654503 core:FurnitureFittingsToolsEquipment 2024-03-31 04654503 core:MotorVehicles 2024-03-31 04654503 bus:Director1 2024-03-31 04654503 bus:Director1 2025-03-31 04654503 bus:Director1 2023-03-31 04654503 bus:Director1 2024-03-31 04654503 bus:Director1 2023-04-01 2024-03-31 04654503 bus:SmallEntities 2024-04-01 2025-03-31 04654503 bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 04654503 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 04654503 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 04654503 bus:FullAccounts 2024-04-01 2025-03-31
Company registration number: 04654503
Fields Pharmacy Limited
Unaudited filleted financial statements
31 March 2025
Fields Pharmacy Limited
Contents
Directors and other information
Statement of financial position
Notes to the financial statements
Fields Pharmacy Limited
Directors and other information

| Director | Mrs Nasim A Ladak
| Company number | 04654503
| Registered office | 38-40 Eldred Avenue
|  | Westdene
|  | Brighton
|  | East Sussex
|  | BN1 5EG
| Business address | 38-40 Eldred Avenue
|  | Westdene
|  | Brighton
|  | East Sussex
|  | BN1 5EG
| Accountants | Pritchard Fellows & Co Ltd
|  | Avery House
|  | 8 Avery Hill Road
|  | London
|  | SE9 2BD

Fields Pharmacy Limited
Statement of financial position
31 March 2025

|  |  | 2025 |  |  |  | 2024 |  |
|  | Note | £ |  | £ |  | £ |  | £
Fixed assets |  |  |  |  |  |  |  |  |
Intangible assets |  | 5 | 420,000 |  |  |  | 420,000 |  |
Tangible assets |  | 6 | 15,442 |  |  |  | 20,417 |  |
|  |  | _______ |  |  |  | _______ |  |
|  |  |  |  | 435,442 |  |  |  | 440,417
Current assets |  |  |  |  |  |  |  |  |
Stocks |  |  | 57,406 |  |  |  | 55,617 |  |
Debtors |  | 7 | 623,547 |  |  |  | 504,201 |  |
Cash at bank and in hand |  |  | 42,265 |  |  |  | 57,271 |  |
|  |  | _______ |  |  |  | _______ |  |
|  |  | 723,218 |  |  |  | 617,089 |  |
Creditors: amounts falling due |  |  |  |  |  |  |  |  |
within one year |  | 8 | ( 693,782) |  |  |  | ( 639,328) |  |
|  |  | _______ |  |  |  | _______ |  |
Net current assets/(liabilities) |  |  |  |  | 29,436 |  |  |  | ( 22,239)
|  |  |  |  | _______ |  |  |  | _______
Total assets less current liabilities |  |  |  |  | 464,878 |  |  |  | 418,178
Creditors: amounts falling due |  |  |  |  |  |  |  |  |
after more than one year |  | 9 |  |  | ( 106,500) |  |  |  | ( 106,500)
|  |  |  |  | _______ |  |  |  | _______
Net assets |  |  |  |  | 358,378 |  |  |  | 311,678
|  |  |  |  | _______ |  |  |  | _______
Capital and reserves |  |  |  |  |  |  |  |  |
Called up share capital |  |  |  |  | 100 |  |  |  | 100
Profit and loss account |  |  |  |  | 358,278 |  |  |  | 311,578
|  |  |  |  | _______ |  |  |  | _______
Shareholder funds |  |  |  |  | 358,378 |  |  |  | 311,678
|  |  |  |  | _______ |  |  |  | _______

For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 08 April 2026 , and are signed on behalf of the board by:
Mrs Nasim A Ladak
Director
Company registration number: 04654503
Fields Pharmacy Limited
Notes to the financial statements
Year ended 31 March 2025
1. General information
The company is a private company limited by shares, registered in United Kingdom. The address of the registered office is Fields Pharmacy Limited, 38-40 Eldred Avenue, Westdene, Brighton, East Sussex, BN1 5EG.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in thereporting period. Tax is recognised in the statement of comprehensive income, except to the extent thatit relates to items recognised in other comprehensive income or directly in capital and reserves. In thiscase, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.Current tax is recognised on taxable profit for the current and past periods. Current tax is measured atthe amounts of tax expected to pay or recover using the tax rates and laws that have been enacted orsubstantively enacted at the reporting date.
Goodwill
The goodwill is considered to have an indefinite life that can be demonstrated, and can be readily measured. The dispensing chemist industry, in which the company operates, has high market entry barriers due to the nature of licence agreements with local health authorities and the limited number available in the marketplace. The value of the business can be ascertained by reference to the current value of goodwill which is payable in the market based on a price per £ in relation to the levels of turnover for each individual pharmacy. The director reviews the value of goodwill on an annual basis and considers it to be worth in excess of net book value.
Tangible assets
tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

| Plant and machinery | - | 10 % | straight line
| Motor vehicles | - | 25 % | reducing balance

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.
Financial instruments
The company holds only basic financial instruments such as cash, other debtors and other creditors, for which carrying amount is equivalent to fair value.
Share-based payments
Equity-settled share-based payment transactions are measured at fair value at the date of grant. The fair value is expensed on a straight-line basis over the vesting period, with a corresponding increase in equity. This is based upon the company's estimate of the shares or share options that will eventually vest which takes into account all vesting conditions and non-market performance conditions, with adjustments being made where new information indicates the number of shares or share options expected to vest differs from previous estimates. Fair value is determined using an appropriate pricing model. All market conditions and non-vesting conditions are taken into account when estimating the fair value of the shares or share options. As long as all other vesting conditions are satsfied, no adjustment is made irrespective of whether market or non-vesting conditions are met. Where the terms of an equity-settled transaction are modified, an expense is recognised as if the terms had not been modified. In addition, an expense is recognised for any increase in the fair value of the transaction, as measured at the date of modification. Where an equity-settled transaction is cancelled or settled, it is treated as if it had vested on the date of cancellation or settlement, and any expense not yet recognised in profit or loss is expensed immediately. Cash-settled share-based payment transactions are measured at the fair value of the liability. Until the liability is settled, the fair value of the liability is re-measured at each reporting date and at the date of settlement, with any changes in fair value recognised in profit or loss for the period.
Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.
Trade debtors
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.
Trade creditors
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 9 (2024: 9 ).
5. Intangible assets

|  | Goodwill |  |  |  |  |
|  | £ |  |  |  |  |
| Cost |  |  |  |  |  |
| At 1 April 2024 and 31 March 2025 | 420,000 |  |  |  |  |
|  | _______ |  |  |  |  |
| Amortisation |  |  |  |  |  |
| At 1 April 2024 and 31 March 2025 | - |  |  |  |  |
|  | _______ |  |  |  |  |
| Carrying amount |  |  |  |  |  |
| At 31 March 2025 | 420,000 |  |  |  |  |
|  | _______ |  |  |  |  |
| At 31 March 2024 | 420,000 |  |  |  |  |
|  | _______ |  |  |  |  |

6. Tangible assets

|  | Fixtures, fittings and equipment | Motor vehicles | Total |  |  |  |
|  | £ | £ | £ |  |  |  |
| Cost |  |  |  |  |  |  |
| At 1 April 2024 and 31 March 2025 | 39,279 | 20,983 | 60,262 |  |  |  |
|  | _______ | _______ | _______ |  |  |  |
| Depreciation |  |  |  |  |  |  |
| At 1 April 2024 | 34,599 | 5,246 | 39,845 |  |  |  |
| Charge for the year | 1,041 | 3,934 | 4,975 |  |  |  |
|  | _______ | _______ | _______ |  |  |  |
| At 31 March 2025 | 35,640 | 9,180 | 44,820 |  |  |  |
|  | _______ | _______ | _______ |  |  |  |
| Carrying amount |  |  |  |  |  |  |
| At 31 March 2025 | 3,639 | 11,803 | 15,442 |  |  |  |
|  | _______ | _______ | _______ |  |  |  |
| At 31 March 2024 | 4,680 | 15,737 | 20,417 |  |  |  |
|  | _______ | _______ | _______ |  |  |  |

7. Debtors

|  |  | 2025 | 2024
|  |  | £ | £
| Trade debtors |  | 79,658 | 74,126
| Other debtors |  | 543,889 | 430,075
|  |  | _______ | _______
|  |  | 623,547 | 504,201
|  |  | _______ | _______

8. Creditors: amounts falling due within one year

|  |  | 2025 | 2024
|  |  | £ | £
| Trade creditors |  | 116,444 | 132,021
| Corporation tax |  | 13,731 | 5,595
| Social security and other taxes |  | 4,307 | 4,975
| Other creditors |  | 559,300 | 496,737
|  |  | _______ | _______
|  |  | 693,782 | 639,328
|  |  | _______ | _______

9. Creditors: amounts falling due after more than one year

|  |  | 2025 | 2024
|  |  | £ | £
| Other creditors |  | 106,500 | 106,500
|  |  | _______ | _______

10. Directors advances, credits and guarantees

| During the year the director entered into the following advances and credits with the company: |  |  |  |  |  |
2025 |  |  |  |  |  |  |
|  | Balance brought forward | Advances /(credits) to the director | Balance o/standing |  |  |
|  | £ | £ | £ |  |  |
| Mrs Nasim A Ladak | ( 482,117) | ( 66,896) | ( 549,013) |  |  |
|  | _______ | _______ | _______ |  |  |
2024 |  |  |  |  |  |  |
|  | Balance brought forward | Advances /(credits) to the director | Balance o/standing |  |  |
|  | £ | £ | £ |  |  |
| Mrs Nasim A Ladak | ( 362,487) | ( 119,630) | ( 482,117) |  |  |
|  | _______ | _______ | _______ |  |  |

The loan is interest free and repayable on demand.
11. Controlling party
The director controlled the company throughout the period.